Inhibition of tumor growth with doxorubicin in a new orthotopically implanted human hepatocellular carcinoma model

Citation
P. Labonte et al., Inhibition of tumor growth with doxorubicin in a new orthotopically implanted human hepatocellular carcinoma model, HEPATOL RES, 18(1), 2000, pp. 72-85
Citations number
29
Categorie Soggetti
Gastroenerology and Hepatology
Journal title
HEPATOLOGY RESEARCH
ISSN journal
13866346 → ACNP
Volume
18
Issue
1
Year of publication
2000
Pages
72 - 85
Database
ISI
SICI code
1386-6346(200007)18:1<72:IOTGWD>2.0.ZU;2-L
Abstract
A number of human xenograft orthotopic models of hepatocellular carcinoma ( HCC) have been previously established by growing histologically-intact pati ent specimens in nude mice. However, the availability of HBV and HCV negati ve human hepatocellular carcinoma specimens is scarce and the pattern of tu mor growth in nude mice varies depending on the tumor type. In the present study, we have established a reproducible xenograft orthotopic model using a human HCC cell line designated HuT7-3 that was derived from two rounds of subcloning of the parental Huh-7 cell line. The tumor growth rate of the H uT7-3 cell line, grown at a primary subcutaneous site, was markedly higher than that of the Huh-7 parental cell line or the human hepatoblastoma Hep-G ? cell line. Furthermore, we have shown that doxorubicin, when administered intravenously, is efficient in inhibiting the development of subcutaneous tumor but leads to the regression of the orthotopic human HCC. Consequently , this novel HCC xenograft orthotopic model can be used for the evaluation of antitumor drugs. (C) 2000 Elsevier Science Ireland Ltd. All rights reser ved.